<div class="infobox infobox-company">
<div class="infobox-header">NeuroSense Therapeutics Ltd.</div>
<div class="infobox-row"><strong>Headquarters:</strong> Netanya, Israel</div>
<div class="infobox-row"><strong>Founded:</strong> 2017</div>
<div class="infobox-row"><strong>Public:</strong> NASDAQ (NRSN)</div>
<div class="infobox-row"><strong>Market Cap:</strong> ~$30M USD (2026)</div>
<div class="infobox-row"><strong>Employees:</strong> ~20</div>
</div>
<div class="infobox infobox-company">
<div class="infobox-header">NeuroSense Therapeutics Ltd.</div>
<div class="infobox-row"><strong>Headquarters:</strong> Netanya, Israel</div>
<div class="infobox-row"><strong>Founded:</strong> 2017</div>
<div class="infobox-row"><strong>Public:</strong> NASDAQ (NRSN)</div>
<div class="infobox-row"><strong>Market Cap:</strong> ~$30M USD (2026)</div>
<div class="infobox-row"><strong>Employees:</strong> ~20</div>
</div>
NeuroSense Therapeutics is a clinical-stage biotechnology company developing novel treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Founded in 2017 and headquartered in Netanya, Israel, the company's lead product, Cognizance (formerly NC-1), is a novel combination therapy targeting multiple pathways involved in neurodegeneration["\^1"].
The company's approach addresses a critical unmet need in ALS: the failure of single-target approaches to meaningfully alter disease progression. By combining multiple neuroprotective agents, NeuroSense aims to achieve synergistic effects that may slow or halt disease progression["\^2"].
NeuroSense was founded based on research from Israeli academic institutions, particularly work on combination therapy approaches for neurodegenerative diseases. The company's scientific approach recognizes that ALS involves multiple pathological pathways, making multi-target therapy essential for meaningful clinical benefit.
Cognizance is NeuroSense's lead clinical candidate for ALS, a novel combination therapy consisting of multiple neuroprotective agents[\^3].
| Attribute | Details |
|-----------|---------|
| Composition | Combination of [NMDA receptor](/entities/nmda-receptor) modulator + antioxidant + anti-inflammatory |
| Mechanism | Multi-target neuroprotection |
| Indication | Amyotrophic Lateral Sclerosis (ALS) |
| Route | Oral |
| Development Phase | Phase 2b (PARADIGM trial) |
| Status | Active clinical development |
Mechanism of Action:
Cognizance works through multiple complementary mechanisms:
Clinical Development:
NC-2 is a preclinical candidate for [Alzheimer's disease](/diseases/alzheimers-disease), leveraging the same multi-target approach[\^4].
| Attribute | Details |
|-----------|---------|
| Mechanism | Multi-target neuroprotection |
| Indication | Alzheimer's Disease |
| Development Phase | Preclinical |
| Status | Active research |
NC-3 is in discovery phase for [Parkinson's disease](/diseases/parkinsons-disease)[\^5].
| Attribute | Details |
|-----------|---------|
| Mechanism | Neuroprotection |
| Indication | Parkinson's Disease |
| Development Phase | Discovery |
| Status | Active research |
NeuroSense's platform is built on the principle that combination therapy is essential for neurodegenerative diseases:
The Phase 2a PARADIGM trial demonstrated[\^6]:
NeuroSense has also conducted biomarker studies showing:
Amyotrophic lateral sclerosis remains a significant unmet medical need:
| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| Amylyx Pharmaceuticals | Relyvrio | Combination (sodium phenylbutyrate/taurursodiol) | Approved |
| BrainStorm Cell Therapeutics | NurOwn | Cell therapy | Phase 3 |
| NeuroSense | Cognizance | Combination therapy | Phase 2b |
| Cytokinetics | Tirasemtiv | Fast skeletal muscle troponin activator | Phase 3 |
| Event | Year | Amount |
|-------|------|--------|
| IPO | 2021 | $25 million (NASDAQ) |
| Public Offering | 2022 | $8 million |
| ATM Offering | 2023 | $15 million |
NeuroSense has established collaborations with: